ABSTRACT-Gene therapy refers to the transfer of specific genes to the host tissue to intervene in a disease process, with resultant alleviation of the symptoms of a particular disease. Cardiovascular gene transfer is not only a powerful technique for studying the function of specific genes in cardiovascular biology and pathobiology, but also a novel and promising strategy for treating cardiovascular diseases. Since the mid1990s, nitric oxide synthase (NOS), the enzyme that catalyzes the formation of nitric oxide (NO) from L-arginine, has received considerable attention as a potential candidate for cardiovascular gene therapy, because NO exerts critical and diverse functions in the cardiovascular system, and abnormalities in NO biology are apparent in a number of cardiovascular disease processes including cerebral vasospasm, atherosclerosis, postangioplasty restenosis, transplant vasculopathy, hypertension, diabetes mellitus, impotence and delayed wound healing. There are three NOS isoforms, i.e., endothelial (eNOS), neuronal (nNOS) and inducible (iNOS). All three NOS isoforms have been used in cardiovascular gene transfer studies with encouraging results. This review will discuss the rationale of NOS gene therapy in different cardiovascular disease settings and summarize the results of experimental NOS gene therapy from various animal models of cardiovascular disease to date.
Introduction
Nitric oxide (NO) exerts critical and diverse functions in the cardiovascular system. It is a pleiotropic molecule that influences a number of cellular processes central to vascular proliferative disease including inhibition of leukocyte adhesion, platelet adhesion, and aggregation, smooth muscle cell proliferation, and synthesis of matrix proteins (1, 2) . Impairment of NO production and /or function plays a key role in a number of cardiovascular disease processes, including atherosclerosis and thrombosis, restenosis, cerebral vasospasm, transplant vasculopathy, hypertension, diabetes mellitus, impotency, and delayed wound healing (1, 2) . While NO therapy under these circumstances is beneficial and highly desirable, the short half-life (several seconds) and high reactivity of NO and the tolerance and other unwanted effects caused by some NO donors (e.g., hypotension) often limit the effectiveness of their clinical applications.
Gene therapy refers to the transfer of functional genes to the host tissue to correct the malfunction of a specific gene or to replace a missing gene, with resultant alleviation of the symptoms of a particular disease (3, 4) . Cardiovascular gene transfer is not only a powerful technique for studying vascular biology but also a novel and promising strategy for treating cardiovascular disease. Accordingly, gene transfer of nitric oxide synthase (NOS) may provide a pleiotropic therapeutic strategy for suppression or modification of the response to cardiovascular injury. Specifically, enhanced NO production from recombinant NOS expression may provide a continuous NO supply to inhibit platelet activation, leukocyte infiltration, platelet-leukocyte interaction, migration of smooth muscle cells and adventitial fibroblasts, endothelial cell apoptosis and matrix synthesis, while stimulating beneficial responses such as re-endothelialization and increased blood flow. These biological properties of NO form the basis of potential NOS gene therapy for a number of cardiovascular disorders in which a dysfunctional L-arginine-NO-cGMP pathway exists. In pursuit of these concepts, a number of investigators including our group have begun to explore the functional influences of NOS gene transfer to the cardiovascular system for the past several years, aiming initially at a variety of animal models of cardiovascular disease, with the long-term goal of applying this technology in future human therapy (5 -8) .
New disease targets are being identified and progresses are being made rapidly in the field.
Principles of cardiovascular gene therapy 2-1. Concept of gene transfer and therapy
Broadly defined, gene therapy encompasses treatments that seek to alter biological processes through the introduction of recombinant DNA to host cells. In pharmacological and therapeutic terms, gene therapy can be considered to be the use of functional genes in the treatment of diseases. In this regard, a prodrug gene (i.e., a cDNA) is delivered to a host by an appropriate vector, via a chosen route of administration (e.g., intraluminal, perivascular, etc.), resulting in the release of the active drug (e.g., an enzyme or protein) after biotransformation processes of the genetic prodrug. An ideal system for gene delivery should consist of a safe formula (the vector) and a drug (the gene product) with maximal therapeutic effects and minimal side effects (3, 4) .
Somatic gene therapy has a fundamental distinction from germ-line gene manipulation. In the former, gene expression is modified only in somatic cells, whereas in the latter, permanent changes are made in the germ-line. In animal species, manipulation of germ-line genes is useful in that it provides models of human genetic disease, helps to elucidate the functions of novel genes, facilitates the large scale production of recombinant therapeutic proteins, and even creates genetically modified animal tissues transferable to humans (i.e., xenotransplantation). In contrast, the aim of somatic gene therapy is to correct the malfunction of a specific gene or to replace a missing gene in a local tissue or organ, without alterations in the human gene pool.
2-2. Vectors for cardiovascular gene transfer
The success of gene therapy depends, to a large extent, on the effectiveness with which the vector system can deliver the functional gene to the host tissue. An ideal vector for cardiovascular gene delivery should have several characteristics. Such would be the capacity to achieve efficient transduction in vivo in both dividing and nondividing vascular cells; maintenance of stable transgene expression for a desired duration; inability to induce the immune response and /or mutagenesis in the host cells. In general, two categories of vector system exist: viral and non-viral vectors (9, 10) . Non-viral vectors are either in the form of naked DNA or plasmid DNA in conjugates (e.g., liposomes, molecular conjugates). Although nonviral vectors possess a very good safety profile for human gene therapy, various attempts to use them for cardiovascular gene transfer have been unsuccessful, attributable to their inability to achieve efficacious in vivo transgene expression.
Viral vectors are produced from wild type viruses by genetic engineering. The recombinant viruses are rendered replication-incompetent by deletion of the particular portions of the viral genome responsible for initiating transcription. However, their ability to infect via interaction of their surface proteins with the receptors on the host cells is maintained. There are a number of viral vectors available for cardiovascular gene transfer. Retroviruses can integrate into the host cell genome and are thus capable of achieving prolonged transgene expression. However, only dividing cells can be transduced -a major drawback for cardiovascular gene transfer. Recombinant adenoviruses are perhaps the most efficient vascular gene transfer vector currently available, owing to their ability to transduce both dividing and non-dividing vascular cells with high efficiency, and to grow to the high titers required for in vivo gene transfer. However, the use of these vectors for human gene therapy has currently been limited by the inflammatory response they provoke in host cells. Recently, an ultraviolet light-inactivated hemagglutinating virus of Japan (HVJ: Sendai virus), a member of the mouse paramyxovirus family, has been combined with multi-or unilamellar liposomes for cardiovascular gene transfer with 30% to 50% transduction efficiency rate and limited toxicity (11) . In addition, adeno-associated virus and lentivirus are currently being developed to address the limitations of other viral vectors. A detailed description of currently available vectors for gene therapy has been reviewed recently (9 -11), which is beyond the scope of this review.
NOS gene transfer and cardiovascular disease 3-1. Cerebral vasospasm
Cerebral vasospasm is a major cause of morbidity and mortality in patients with subarachnoid hemorrhage. The spastic cerebral arteries do not respond well to the currently available vasodilators. Impairment of NO production and /or vasodilator function is an important mechanism associated with the pathogenesis of cerebral vasospasm, accompanied by decreased endothelial NOS (eNOS) mRNA level, loss of neuronal NOS (nNOS) immunoreactivity, and diminished cGMP formation (8, 12) . Consequently, experimental vasospasm can be alleviated with NO or NO donors because of their potent relaxing function. However, the short half-life of NO and the unwanted effects of NO donors (e.g., hypotension) limit their clinical usefulness. In contrast, eNOS gene transfer to cerebral arteries raises the possibility of providing continuous NO supply to the underlying smooth muscle cells (SMCs) (13) . Cerebral vasospasm is a transient phenomenon, usually occurring between 4 and 12 days after subarachnoid hemorrhage. Thus, adenoviral-mediated eNOS gene transfer may be useful in this setting for its transient nature (8) .
In vivo eNOS gene transfer to the canine cerebral vasculature was successfully achieved by delivering genes to the perivascular site via cerebrospinal fluid, using adenoviral vector injection into the cisterna magna (14) . In cerebrovascular gene transfer, perivascular administration is advantageous over intraluminal delivery which requires the interruption of cerebral blood flow. In vivo eNOS gene transfer with such an approach resulted in recombinant eNOS expression localized in the adventitial fibroblasts of major cerebral arteries and improved vasorelaxation to bradykinin. The improved vasorelaxation was adventitiadependent, since the transgene was not expressed in SMCs, and removal of endothelium did not affect relaxation (14, 15) . Surprisingly, the adventitia-dependent relaxation after eNOS gene transfer was also produced by certain vasoconstrictors such as angiotensin II and endothelin-1 (16 -18) , which raises a novel concept that successful transfer and expression of recombinant eNOS gene can lead to a qualitative change in responsiveness to vasoconstrictors. Taken together, these findings suggest that genetically modified adventitia can produce NO and cause relaxation in cerebral arteries, and may have beneficial effects in the prevention and treatment of subarachnoid hemorrhageinduced cerebral vasospasm. Indeed, ex vivo eNOS gene transfer to spastic canine cerebral arteries following subarachnoid hemorrhage resulted in partial restoration of impaired NO-mediated relaxations (19) . Recently, in a dog model of subarachnoid hemorrhage, in vivo eNOS gene transfer increased NO levels in cerebrospinal fluid and improved vascular relaxations to bradykinin, endothelin-1 (20) , as well as the NO precursor L-arginine plus cofactor tetrahydrobiopterin (21) , resulting in alleviation of vasospasm. Adenoviral-mediated gene transfer to human cerebral arteries ex vivo has also been reported recently (8, 22) . Consistent with the results from animal studies, expression of recombinant eNOS in human pial arteries occurs mainly in adventitial fibroblasts where it augments relaxations to NO-dependent agonists such as bradykinin. Hence, adenoviral-mediated eNOS gene transfer to human cerebral arteries is feasible.
3-2. Atherosclerosis
Endothelial dysfunction due to impaired L-arginine /NO pathway is an early feature of atherosclerosis, which often leads to changes in endothelial redox state, activation of oxidant-sensitive transcriptional genes (e.g., monocyte chemoattractant protein-1, vascular cell adhesion molecule), adhesion of circulating platelets and monocytes, increased accumulation of lipids in the intima, and increased contraction, migration, and proliferation of SMCs (23) . Progressive development of atherosclerotic lesions results in the formation of lipid-laden plaques that are prone to fissure, ulceration, and rupture. Thrombosis resulting from the plaque rupture in the coronary arteries plays a pivotal role in the progression from atherosclerosis to myocardial infarction. Hence, NOS gene therapy might be expected to improve endothelium-dependent vasodilation, reverse the altered endothelial redox state (thus decreasing adhesion molecule secretion and endothelial adhesiveness), suppress SMC proliferation, and stabilize vulnerable plaques.
Both ex vivo and in vivo NOS gene transfer to atherosclerotic arteries have been studied. In isolated aortas and carotid arteries from hypercholesterolemic rabbits, ex vivo eNOS gene transfer using adenoviral vectors improved acetylcholine-induced endothelium-dependent vasodilation (24, 25) . Recombinant eNOS expression was evident in both endothelial cells and adventitia 24 h after transduction. L-Arginine availability was not a limiting factor for recombinant eNOS activity (26) . Consistent with these results, in vivo intraluminal delivery of nNOS and eNOS genes to the carotid artery of cholesterol-fed rabbits ameliorated the impaired endothelium-dependent vasodilation in response to acetylcholine, respectively (27 -30) . Regression of atherosclerosis was also observed 1 -3 days after nNOS gene transfer, as evidenced by reduction of vascular adhesion molecule expression, T-lymphocyte and monocyte infiltration, and lipid deposition (31) . These findings imply the potential of NOS gene therapy for human atherosclerosis. Further studies in this field need to investigate whether in vivo NOS gene transfer can reverse pathological changes of atherosclerotic arteries. Additionally, the plaque stabilization of NOS gene transfer must be explored in an animal model that mimics atherosclerotic plaque rupture, because this effect has an important clinical significance in preventing deterioration of the disease.
3-3. Restenosis
Percutaneous transluminal coronary angioplasty (PTCA) has become a mainstay in the treatment of ischemic heart disease. However, this therapy is limited by the development of intimal hyperplasia. Restenosis occurs in 30% to 50% of patients and currently there are no effective pharmacological agents for such a complication (32) . Endogenous NO in the vasculature is vasoprotective by inhibiting platelet and leukocyte adhesion, inhibiting SMC proliferation and migration, and promoting endothelial survival and proliferation (1, 2) . At sites of vascular injury following angioplasty, the endothelium is disrupted and NO synthesis is impaired. Hence, augmenting local NO synthesis through NOS gene transfer may help arrest the proliferative response to vascular injury.
In 1995, von der Leyen et al. delivered eNOS gene to balloon-injured rat carotid arteries using HVJ-liposomes and demonstrated a 70% reduction in neointimal formation 2 weeks after balloon injury (33). Chen et al. seeded SMCs engineered to express eNOS using retrovirus onto the lumi-nal surface of balloon-injured rat carotid arteries and inhibited neointimal formation by 37% at 2 weeks postinjury (34) . Other studies have similarly shown that adenoviral delivery of eNOS to balloon-injured rat and porcine arteries can limit intimal hyperplasia for up to 4 weeks (35 -37) . Recently, the effect of eNOS and plasminogen activator inhibitor 1 (PAI-1) gene transfer on neointimal formation was compared in balloon-injured porcine coronary arteries (38) . Adenoviral-mediated eNOS but not PAI-1 gene transfer could significantly inhibit the neointimal formation, at 4 weeks after intramural gene delivery. No acute systemic toxicity was observed after gene transfer. The results suggest that local gene transfer of eNOS may hold promise as a safe and effective adjunctive treatment to prevent postangioplasty restenosis. In addition to constitutive eNOS gene transfer, inducible NOS (iNOS) gene transfer has been investigated in balloon-injured arteries (39) . Adenoviralmediated iNOS gene transfer to injured rat carotid artery using 100-to 1000-fold lower virus concentrations (2´10 6 pfu) than most other vascular gene therapy studies resulted in a near complete reduction (>95%) in neointimal formation up to 6 weeks post injury. In injured pig iliac artery, iNOS gene transfer led to a >50% decrease of intimal hyperplasia, again using much less (3-to 20-fold less) virus (5´10 8 pfu) than eNOS or nNOS gene delivery studies. This remarkable degree of suppression of restenosis was observed in both models when gene transfer was initiated shortly after balloon injury. However, iNOS gene transfer did not result in regression of preformed neointimal lesions when gene transfer was carried out several days after balloon injury, suggesting gene therapy during the early stage of vessel injury is a determining factor for a successful outcome. Transfer of iNOS gene in this setting may be advantageous over eNOS or nNOS transduction since a substantially lower amount of adenovirus encoding iNOS seems to produce a therapeutic effect. This would decrease the likelihood of adenoviral vector-induced cytotoxicity.
3-4. Autograft vasculopathy
Vein graft stenosis: Coronary artery bypass grafting is now the most commonly performed surgical therapy for ischemic heart disease. Although internal mammary artery is the preferred choice because of its superior patency rate, saphenous vein is the most commonly used conduit due to its availability and versatility in reaching distal coronary branches that cannot be bypassed with the internal mammary artery. However, it is prone to the development of vein graft stenosis with a relatively poor 10-year patency rate, resulting from thrombotic occlusion in the early postoperative period and intimal hyperplasia and atherosclerosis in late postoperative period (40) . Traditional pharmacotherapeutic approaches have not significantly ameliorated the disease course, and reoperations are required with high morbidity and mortality. These promote the search for effective local gene therapy, as there is an ideal window of opportunity for ex vivo gene transfer during harvesting and preparation of autologous veins for grafting. Since NO is known to inhibit many of the processes involved in graft failure such as thrombus formation and SMC cell proliferation, NOS gene transfer may reduce the vein graft occlusion through restoration and /or augmentation of NO production in the vein grafts (41) .
Ex vivo eNOS gene transfer using adenoviral vectors increased NO production and NO-dependent relaxation and inhibit intimal hyperplasia in cultured human saphenous veins (42, 43) . Gene transfer of eNOS has also been carried out in autologous femoral vein grafts prior to their implantation to ipsilateral femoral arteries in a dog model (44) . Increased local NO production, as a result of recombinant eNOS expression mediated by HVJ-liposomes, inhibited more than 50% of intimal hyperplasia in the vein grafts with poor runoff 4 weeks after the operation. In a rabbit jugular-carotid interposition bypass graft model, nNOS gene transfer to the venous grafts prior to their bypass resulted in decreased inflammatory adhesion molecule expression in the early stage (7 days) and reduced superoxide levels and intimal hyperplasia in the late stage (28 days) following bypass surgery (45) . Similarly, gene transfer of iNOS to jugular vein grafts in a porcine model of jugular-carotid interposition before bypass resulted in reduced smooth muscle proliferation and intimal /medial ration in the grafts in early and late stages after bypass, respectively (46) . These results suggest the potential for NOS gene therapy of vein grafts to prolong graft patency. However, there is yet little information on NOS gene transfer on vein graft atheroma. The advent of a convenient mouse model of vein grafting (47) together with the development of helper-dependent adenoviruses and adeno-associated viruses that extend transgene expression promises a breakthrough in this subject.
Arterial graft spasm: Radial arteries represent another choice for coronary artery bypass because they are relatively resistant to atherosclerosis compared with saphenous veins, and they expand the range of coronary bypass compared with internal mammary arteries. However, radial artery grafts are prone to developing arterial spasm, with poor early patency rate. Augmentation of NO production in radial artery conduits via NOS gene transfer may provide an effective means to antagonize the vasospasm, hence improving early patency rate.
After adenoviral-mediated eNOS gene transfer to human radial arteries ex vivo, both KCl and prostaglandin F2=-induced contractions were reduced by more than 50% in transduced arteries compared to the controls (48), suggesting that eNOS gene therapy may exert an important role in prevention of radial artery graft spasm. However, similar results need to be obtained in the animal models of artery grafting, in order to support potential clinical applications in the future.
3-5. Cardiac allograft diseases
Accelerated coronary atherosclerosis is the major factor limiting long-term survival after cardiac transplantation, and it is the major cause of allograft dysfunction and late death in patients. In addition, acute rejection and ischemiareperfusion injury are involved in acute allograft dysfunction. Both eNOS and iNOS may play a protective role in allografts, since eNOS or iNOS deficiency exacerbates the development of allograft atherosclerosis (49, 50) . In allografts, there exists dysfunctional endothelium and impaired eNOS activity as a result of ischemia or native atherosclerosis (49) . As a result of the use of immunosuppressive agents, downregulation of iNOS expression accelerates the atherosclerosis process as well (50) . NO produces potent vasodilation and inhibits platelet aggregation, leukocyte adhesion, and SMC proliferation and migration, all of which are advantageous in combating allograft atherosclerosis. NOS gene transfer to the allograft heart is feasible, since there is an up to 4-h time period from organ retrieval to transplantation when the donor heart can be subjected to ex vivo gene transfer.
Transduction of the rat or mouse aortic allografts ex vivo with iNOS using an adenoviral vector completely prevented the development of allograft atherosclerosis (50) . The results were further confirmed in a rat cardiac allograft model (51) . Coronary intimal hyperplasia in allografts was significantly inhibited by ex vivo iNOS gene transfer to the heart using a recirculatory system and such beneficial effect was observed as late as 90 days (51) . In addition, ex vivo eNOS gene transfer for preventing cardiac allograft diseases has been explored. In rabbit carotid allografts, liposome-mediated eNOS gene transfer markedly reduced neointimal formation, accompanied by reduced T-lymphocyte and macrophage infiltration and adhesion molecule expression in transplanted arteries (52) . In an allogeneic rabbit heart transplant model, liposome-mediated eNOS gene transfer to the donor hearts through intracoronary infusion reduced ischemia-reperfusion injury by inhibiting NFk B activation, adhesion molecule expression, and leukocyte infiltration 24 h after transplantation (53) . Without immunosuppression, eNOS-transduced hearts survived longer than the controls. The important subject of interaction between immunosuppression and transgene expression has also been investigated (51) . Immunosuppression with cyclosporine A inhibited endogenous iNOS expression in the aortic allografts, while it did not affect recombinant iNOS expression since the CMV-driven promoter of the adenoviral vector was not subjected to transcriptional inhibition (51) . Furthermore, transgene expression using adenoviral vectors was prolonged by immunosuppression in the rat heart transplant model (54) . The explanation for this effect may be that immunosuppression also inhibits the immune response to adenoviral vectors which limits the duration of transgene expression. Therefore, the need for immunosuppression in the setting of heart transplantation appears not to affect the beneficial effects obtained from NOS gene transfer.
3-6. Hypertension
Essential hypertension: Essential hypertension is a multifactorial and polygenic disorder and affects approximate 20% of the adult population. As a vasodilator, NO plays an important role in the regulation of blood pressure physiologically. A defect of the eNOS gene has been implicated in the pathogenesis of both animal (55) and human hypertension (56 -59) . Augmentation of NO may thus be a reasonable approach for the treatment of hypertension. In fact, sodium nitroprusside, a NO donor, has been used as an antihypertensive agent since the mid-1950s. However, because of its short duration of action, need for continuous intravenous infusion, and unwanted effects of hypotension and thiocyanate toxicity, it is only occasionally used for short-term control of hypertensive crisis. NOS gene therapy may provide the possibility for long-term control of hypertension by continuous NO production.
Gene transfer of eNOS has been used to counter the increased oxidative stress-induced vascular dysfunction and atherogenesis in hypertension. In both angiotensin IIinduced and spontaneously hypertensive rats (SHR), enhanced superoxide production impairs endothelium-dependent NO-mediated relaxation and contributes to atherogenesis by augmenting vascular cellular adhesion molecule-1 (VCAM-1) expression. Several studies using local gene delivery with adenoviral vectors have demonstrated that eNOS gene transfer restored NO-dependent vasomotor function in the arteries of eNOS knockout mice as well as in rats of SHR and angiotensin II hypertensive models (60 -62) . In deoxycorticosterone acetate (DOCA)-salt hypertension, a model with suppressed plasma renin and angiotensin levels, vascular superoxide level is also markedly increased (63), possibly due to enhanced endothelin-1 (ET-1) levels in the vessel wall (64) . Gene transfer of eNOS effectively reduced superoxide levels in carotid and femoral arteries, two vessel types prone to the development of atherosclerosis. Increased VCAM-1 levels were concomitantly reduced after eNOS gene transfer (65) . Hence, eNOS gene transfer may be an effective means in combating superoxide-induced vascular dysfunction and atherogenesis in hypertension. Moreover, a study in spontaneously hypertensive rats (SHR) has reported that a single injection of the naked eNOS plasmid DNA through the tail vein caused a significant reduction of blood pressure for 6 weeks, and a second injection maintained the effect up to 12 weeks (66) . In this study, increased NO production was determined as increased urinary and serum nitrite /nitrate content as well as increased cGMP levels in the urine and aorta. Somatic delivery of eNOS gene using such a non-viral vector may be both safe and useful as a means for the treatment of essential hypertension.
Pulmonary hypertension: Pulmonary hypertension is a disease with high morbidity and mortality. The drugs currently in use are anticoagulants, calcium-channel antagonists, and intravenous prostacyclin and inhaled NO. Despite these treatment regimens, the mortality rates due to pulmonary hypertension are still high. For this reason, investigators have turned their attention to explore a gene therapy strategy. Since reduced expression of eNOS and diminished endothelium-dependent relaxation are involved in pulmonary hypertension (67) , transfer of eNOS gene may also reduce vascular resistance of the pulmonary circulation and provide a local therapeutic approach to pulmonary hypertension.
Functional expression of eNOS transgene in the lung has been successfully achieved. In vivo eNOS gene delivery using aerosolization or intratracheal instillation produces transgene expression mainly located in airways, alveoli and small and medium-sized pulmonary vessels (68, 69) . Ex vivo eNOS gene delivery using cell-based gene transfer via venous circulation can also achieve localized transgene expression in the lung, predominantly manifested in alveoli and pulmonary microvasculature (70) . Both adenoviraland nonviral-mediated eNOS gene transfer can reduce acute and chronic pulmonary hypertension in rats and mice and attenuate the right ventricular hypertrophy caused by chronic pulmonary hypertension. No change in systemic pressure was observed in these studies. Recently, iNOS gene therapy has been explored and compared with eNOS gene transfer (71) . Adenoviral-mediated iNOS gene transfer (3´10 9 pfu) using aerosolization significantly reduced chronic hypoxic pulmonary hypertension, pulmonary vascular remodeling and right ventricular hypertrophy in rats. However, the same dose of eNOS gene transfer had no effects on these parameters. These ineffective results with eNOS may be at least related to the low dose, since previous a study showed that chronic pulmonary hypertension could be inhibited by a higher dose (10 12 pfu) of adenoviralmediated eNOS gene transfer (67) . Thus, with the same dose, iNOS gene transfer to the lung may be a more effective means for alleviating pulmonary hypertension.
Portal hypertension: Portal hypertension is a major complication of cirrhosis and has profound clinical consequences, many of which are associated with substantial morbidity and mortality. The pathological basis of portal hypertension is complex and involves multiple factors.
Recent studies indicate that diminished NO release due to eNOS dysfunction in sinusoidal endothelial cells combined with augmented stellate cell contractility due to unbalance of endothelin-1 and NO production contribute to increased intrahepatic resistance and portal hypertension (72) . Nitrovasodilators are capable of ameliorating portal (intrahepatic) resistance; however, systemic administration of these agents is accompanied by excessive peripheral vasodilation resulting in significant side effects. This problem may be circumvented by NOS gene therapy, because intravenous administration of adenoviral vectors preferentially targets the liver.
In normal rats, in vivo adenoviral-mediated eNOS gene transfer significantly increased eNOS protein levels and catalytic activity in the liver and diminished baseline perfusion pressure and constriction in response to methoxamine in the perfused liver one week after gene delivery (73) . In cirrhotic rats, in vivo nNOS gene transfer with adenoviral vectors through the femoral vein reduced intrahepatic resistance and portal hypertension (74) . Expression of recombinant NOS was mainly located in sinusoidal endothelial and stellate cells and hepatocytes. Transduction efficiency was reduced in injured compared to normal liver (74) . This implies that to achieve comparable gene expression in the injured liver, higher adenoviral titers may be required, and raises another problem of hepatotoxicity induced by higher adenoviral concentrations. Alternatively, newer adenoviral constructs that lack viral coding sequences or those that contain specific promoters may help circumvent this dosedependent toxicity.
3-7. Diabetes mellitus
Accelerated atherosclerosis is the major cause of death in patients with diabetes mellitus. Impairment of endotheliumdependent relaxation in response to acetylcholine is observed both in humans and in animal models of diabetes mellitus, and believed to be associated with endothelial injury due to accumulation of advanced glycation end products and excess formation of reactive oxygen species. Adenoviral-mediated eNOS gene transfer to the aortas and carotid arteries ex vivo has been used to improve acetylcholine-induced vasodilation in a rabbit model of type 1 diabetes (75, 76) . Transgene expression of recombinant eNOS was observed in both endothelium and adventitia 24 h following transduction. However, it will be necessary to establish these beneficial effects with in vivo gene transfer studies, especially if the approach were to move towards gene therapy.
3-8. Impotence
NO is the principal mediator of penile erection and all three isoforms of NOS enzymes contribute to endogenous NO production in the penis (77) . In aging and in diabetic states, erectile dysfunction due to the inability of the cavernosal smooth muscle to undergo complete relaxation is accompanied by a decrease in penile NOS activity. The use of NO donors and inhibitors of cGMP breakdown, while beneficial in ameliorating impotence, can cause side effects. Localized and targeted augmentation of NO release via NOS gene transfer to cavernosal smooth muscle and endothelial cells of the penile tissue may represent an alternative means for the treatment of impotence. Several studies have demonstrated that intracavernosal administration of naked iNOS cDNA or adenoviral-mediated eNOS gene transfer can mitigate the aging-related erectile dysfunction in rats, with no pathological changes in the penis (78 -80) . After adenoviral-mediated eNOS gene transfer injected into the penis, local functional expression of recombinant eNOS is confirmed by increase in eNOS protein and cGMP levels in the corpora cavernosa, while local iNOS protein and plasma cGMP levels remained unchanged.
3-9. Wound healing
Endogenous NO plays a key role in wound healing (81) . It promotes processes central to wound healing such as angiogenesis and migration and proliferation of fibroblasts, epithelial cells, and endothelial cells. Accordingly, topical application of a NO donor has been shown to accelerate closure of excisional wounds in rats (82) , while NOS inhibitors retard wound healing (83) . In contrast, wound closure is significantly delayed in iNOS or eNOS knockout mice compared with wild-type controls (84, 85) . The possibility that recombinant NOS expression may promote endothelial regeneration after injury (hence accelerating vascular healing) has been investigated in iNOS knockout mice subjected to excisional wounding (85) . Delayed wound healing was completely reversed by adenoviral mediated iNOS gene transfer at the time of wounding. In male Sprague-Dawley rats that received a longitudinal dorsal midline incision, plasmid-mediated iNOS gene transfer with or without liposomes resulted in recombinant iNOS expression and augmented NO production, which preceded an increase in collagen synthesis and accumulation (86) . The results from these studies suggest that iNOS gene transfer may improve wound healing process in NOS-deficient states such as aging and diabetes as well as during steroid treatment.
Future directions
Over the last several years, the feasibility of recombinant NOS gene transfer to various cardiovascular beds has been established ex vivo and in vivo in a number of diseased animal models and human tissues. Localized vascular NOS gene expression is advantageous over NO supplementation by either NO or NO donor agents. However, several obstacles have to be overcome before NOS gene therapy can enter the clinical arena. In addition to choosing an appropriate isoform of NOS for gene transfer to specific vascular cells, a major issue is the limitations of currently available vectors. Another clinically formidable obstacle is to find an effective means to deliver the vectors to the vessel wall. Improvements in both vector design and in vivo gene delivery methods are therefore required prior to the clinical application of recombinant NOS gene therapy. Finally, caution is necessary regarding NOS overexpression in situations where the adverse consequences of NO-free radical interactions may outweigh the direct benefits of NO alone (5, 7).
